Activating mutations in these genes have been frequently identified in many types of cancer and have been shown to result in hyper-activation of the PI3K/AKT/mTOR signaling pathway [14,15,56,76,77,78,79,80,81,82,83]. This evidence concerns the gene MTOR and cancer.